Supplementary Figure S1 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas | Synapse
July 15, 2025
Supplementary Figure S1 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
Puntos clave
MAIN FINDING: The trial explores the combination of doxorubicin with two antibodies in advanced soft tissue sarcomas.
KEY EVIDENCE: Outcomes from the trial indicate potential therapeutic benefit in treating metastatic soft tissue sarcomas.
APPROACH: This study utilized a single-arm phase 2 trial design focusing on treatment schedules.
SIGNIFICANCE: Results may contribute to new treatment strategies for difficult-to-treat advanced sarcomas.